QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 moderna-faces-analyst-downgrades-amid-revised-rd-restructured-strategy-and-delayed-profitability-target

Moderna announces plans to reduce R&D spending by $1.1 billion by 2027, focusing on ten key products. Analysts highlight ne...

Core News & Articles

https://www.nbcnews.com/health/health-news/florida-covid-shots-mrna-vaccines-older-adults-rcna170997Even as the Covid wave in F...

 b-of-a-securities-maintains-neutral-on-moderna-lowers-price-target-to-110

B of A Securities analyst Geoff Meacham maintains Moderna (NASDAQ:MRNA) with a Neutral and lowers the price target from $130...

 td-cowen-maintains-hold-on-moderna-lowers-price-target-to-60

TD Cowen analyst Tyler Van Buren maintains Moderna (NASDAQ:MRNA) with a Hold and lowers the price target from $70 to $60.

 rbc-capital-maintains-sector-perform-on-moderna-lowers-price-target-to-75

RBC Capital analyst Luca Issi maintains Moderna (NASDAQ:MRNA) with a Sector Perform and lowers the price target from $90 to ...

 jp-morgan-downgrades-moderna-to-underweight-lowers-price-target-to-70

JP Morgan analyst Jessica Fye downgrades Moderna (NASDAQ:MRNA) from Neutral to Underweight and lowers the price target from ...

 jefferies-downgrades-moderna-to-hold-lowers-price-target-to-65

Jefferies analyst Michael Yee downgrades Moderna (NASDAQ:MRNA) from Buy to Hold and lowers the price target from $120 to $65.

 oppenheimer-downgrades-moderna-to-perform

Oppenheimer analyst Hartaj Singh downgrades Moderna (NASDAQ:MRNA) from Outperform to Perform.

 piper-sandler-maintains-overweight-on-moderna-lowers-price-target-to-115

Piper Sandler analyst Edward Tenthoff maintains Moderna (NASDAQ:MRNA) with a Overweight and lowers the price target from $15...

 needham-reiterates-hold-on-moderna

Needham analyst Joseph Stringer reiterates Moderna (NASDAQ:MRNA) with a Hold.

 wall-street-eyes-strong-finish-to-the-week-despite-futures-suggesting-moderation-in-tech-buying-strategist-cautions-against-factoring-rapid-steep-cuts-ahead-of-next-weeks-fed-meeting

Now that the twin inflation reports are in the rearview mirror, U.S. stocks are hanging onto the slender optimism as traders lo...

 why-are-novavax-shares-trading-lower-today

Novavax Inc. (NASDAQ: NVAX) shares are trading lower Thursday following multiple significant announcements. Here's what you...

 stocks-edge-up-as-producer-inflation-supports-rate-cut-bets-small-caps-miners-rally-whats-driving-markets-thursday

At midday on Thursday, Wall Street was showing slight gains, with small caps leading the charge. The Russell 2000 index surged ...

Core News & Articles

- Reuters Citing State TV

 moderna-to-launch-skin-cancer-vaccine-as-soon-as-2025-ceo---nikkei

https://asia.nikkei.com/Business/Pharmaceuticals/Moderna-to-launch-skin-cancer-vaccine-as-soon-as-2025-CEO

 moderna-ceo-says-rsv-vaccine-uptake-in-the-us-is-slower-than-anticipated

- Investor Conference

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION